



EXHIBITOR SPOTLIGHT

Taking a Different Direction in the Treatment of Primary Hyperoxaluria Type 1 (PH1)

This session will introduce an FDA-approved therapy for patients with Primary Hyperoxaluria Type 1 (PH1) that can help address the underlying cause of the disease. PH1 is a rare, autosomal recessive genetic disorder that leads to kidney stones and progressive kidney damage. It is caused by a genetic mutation that results in the excessive production of oxalate by the liver. Attend this session to learn more about PH1 and a treatment option that can help address the overproduction of oxalate.

Dr. Deepa Malieckal is a nephrologist in New York and is affiliated with multiple hospitals in the area, including Brooklyn Hospital Center and Long Island Jewish Medical Center at Northwell Health. She received her medical degree from State University of New York Downstate Medical Center College of Medicine and completed her Internal Medicine Residency at Zucker School of Medicine at Hofstra in New York. Dr. Deepa Malieckal has expertise in treating chronic kidney disease, hypertension, kidney disease, among other conditions. She has published an assortment of scientific articles, had CBS publicized news interviews, and college presentations nationwide.



Deepa Alicia Malieckal, MD

Lunch will be provided.

DATE: Saturday, November 8, 2025

TIME: 11:30 AM - 12:15 PM

**LOCATION: George R. Brown Convention Center, Houston, TX
Exhibit Hall D, Theater #3**

Sponsored by Novo Nordisk Inc.



Please note this is a promotional presentation; it will not be certified for continuing medical education credit.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

All other trademarks, registered or unregistered, are the property of their respective owners.

© 2025 Novo Nordisk All rights reserved. US25RREN00047 September 2025